Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 3/20 | 0.76 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.72 |
| ▸ | CASP6 | P55212 | 2/20 | 0.52 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.52 |
| ▸ | NT5E | P21589 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.44 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29349608 | 0.86 | PRMT1 (1.00) | PRMT1SIRT1CASP6CTDSP1NT5E | |
| SCHEMBL6078889 | 0.86 | PRMT1 (0.78) | PRMT1SIRT1CASP6CTDSP1NT5E | |
| SCHEMBL2679101 | 0.86 | PRMT1 (1.00) | PRMT1SIRT1CASP6CTDSP1NT5E | |
| SCHEMBL6079067 | 0.86 | PRMT1 (1.00) | PRMT1SIRT1CASP6CTDSP1NT5E | |
| SCHEMBL29352560 | 0.84 | PRMT1 (1.00) | PRMT1SIRT1CASP6CTDSP1NT5E | |
| SCHEMBL6079061 | 0.84 | PRMT1 (1.00) | PRMT1SIRT1CASP6CTDSP1NT5E | |
| SCHEMBL10014033 | 0.79 | PRMT1 (0.84) | PRMT1SIRT1CASP6CTDSP1NT5E | |
| SCHEMBL18134576 | 0.79 | PRMT1 (0.84) | PRMT1SIRT1CASP6CTDSP1NT5E | |
| SCHEMBL11342001 | 0.78 | PRMT1 (0.82) | PRMT1SIRT1CASP6CTDSP1NT5E | |
| SCHEMBL6077871 | 0.78 | CA2 (0.59) | PRMT1SIRT1CA2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071231-B2 | Naphthalene ureas as glucose uptake enhancers | TELIK, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1181271-B1 | NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS | TELIK INC (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1355698-A2 | INSULIN RECEPTOR ACTIVATORS FOR THE TREATMENT OF METABOLIC DISORDERS IN HUMANS RESULTING FROM TREATMENT OF HIV INFECTION WITH HIV PROTEASE INHIBITORS | TELIK, INC. (US) | 2003-10-29 | — | — | EP | disclosed |
| WO-2003085127-A2 | METHOD FOR IDENTIFICATION OF INSULIN RECEPTOR KINASE ACTIVATORS | TELIK, INC. (US) | 2003-10-16 | — | — | WO | disclosed |
| US-20030135063-A1 | Novel naphthalene ureas as glucose uptake enhancers | SPEVAK WAYNE R (US) | 2003-07-17 | — | — | US | disclosed |
| US-6528037-B2 | Via administering HIV protease inhibitor and glucose to rats and measuring the increases in plasma | TELIK, INC. | 2003-03-04 | — | — | US | disclosed |
| US-20020151542-A1 | Method for determining whether a compound is an insulin receptor kinase activator | TELIK, INC. | 2002-10-17 | — | — | US | disclosed |
| US-6458998-B1 | NAPHTHALENEUREAS AS ANTIDIABETIC AGENTS | TELIK, INC. | 2002-10-01 | — | — | US | disclosed |
| US-20020061927-A1 | Insulin receptor activators for the treatment of metabolic disorders induced by treatment with HIV protease inhibitors | TELIK, INC. | 2002-05-23 | — | — | US | disclosed |
| WO-2002030514-A2 | INSULIN RECEPTOR ACTIVATORS FOR THE TREATMENT OF METABOLIC DISORDERS IN HUMANS RESULTING FROM TREATMENT OF HIV INFECTION WITH HIV PROTEASE INHIBITORS | TELIK, INC. (US) | 2002-04-18 | — | — | WO | disclosed |
| EP-1181271-A2 | NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS | Telik, Inc. (US) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000071506-A9 | NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS | TELIK INC (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2000071506-A2 | NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS | TELIK, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151542-A1 | Method for determining whether a compound is an insulin receptor kinase activator | INSR, GPR119, IRS1 | PRMT1 3058/4885SIRT1 1556/4885CASP6 1110/4885 |
| US-20020061927-A1 | Insulin receptor activators for the treatment of metabolic disorders induced by treatment with HIV protease inhibitors | GPR119, LIPE, PNLIP | PRMT1 2604/4885SIRT1 1632/4885CASP6 1863/4885 |
| US-20030135063-A1 | Novel naphthalene ureas as glucose uptake enhancers | GPR119, SLC2A8, SLC2A1 | PRMT1 2899/4885SIRT1 1910/4885CASP6 4610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.